(VIANEWS) – EUROFINS SCIENT. (ERF.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Diagnostics & Research industry.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| EUROFINS SCIENT. (ERF.PA) | €54.90 | 2.16% | 9.12% |
| LUMIBIRD (LBIRD.PA) | €12.10 | 1.25% | 5.68% |
| BIOMERIEUX (BIM.PA) | €101.45 | 0.81% | 9.87% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. EUROFINS SCIENT. (ERF.PA)
2.16% Forward Dividend Yield and 9.12% Return On Equity
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 130,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, training and consulting; and testing for persistent organic pollutants, dioxins and organic contaminants, pesticides, mycotoxins, allergens, and pathogens and vitamins, as well as analyses for genetic modifications. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and technologies services. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
Earnings Per Share
As for profitability, EUROFINS SCIENT. has a trailing twelve months EPS of €2.28.
PE Ratio
EUROFINS SCIENT. has a trailing twelve months price to earnings ratio of 24.08. Meaning, the purchaser of the share is investing €24.08 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.12%.
Volume
Today’s last reported volume for EUROFINS SCIENT. is 102783 which is 67.31% below its average volume of 314442.
More news about EUROFINS SCIENT..
2. LUMIBIRD (LBIRD.PA)
1.25% Forward Dividend Yield and 5.68% Return On Equity
Lumibird SA designs, manufactures, and sells various lasers for the scientific, industrial, and medical applications worldwide. It operates in two segments, Photonics and Medical. The company offers solid-state and diode lasers, fiber lasers, fiber lasers/amplifiers and components, Laser rangefinder and LiDAR wind doppler LiDAR, medical and ophthalmological equipment. Its products are used in various applications, such as industrial and scientific, defense and space, and lidar sensors. The company was incorporated in 1970 and is headquartered in Lannion, France.
Earnings Per Share
As for profitability, LUMIBIRD has a trailing twelve months EPS of €0.45.
PE Ratio
LUMIBIRD has a trailing twelve months price to earnings ratio of 26.89. Meaning, the purchaser of the share is investing €26.89 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.68%.
Volatility
LUMIBIRD’s last week, last month’s, and last quarter’s current intraday variation average was a positive 3.88%, a negative 0.22%, and a positive 1.99%.
LUMIBIRD’s highest amplitude of average volatility was 4.14% (last week), 1.91% (last month), and 1.99% (last quarter).
Yearly Top and Bottom Value
LUMIBIRD’s stock is valued at €12.10 at 11:40 EST, below its 52-week low of €13.04.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, LUMIBIRD’s stock is considered to be oversold (<=20).
More news about LUMIBIRD.
3. BIOMERIEUX (BIM.PA)
0.81% Forward Dividend Yield and 9.87% Return On Equity
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Earnings Per Share
As for profitability, BIOMERIEUX has a trailing twelve months EPS of €3.25.
PE Ratio
BIOMERIEUX has a trailing twelve months price to earnings ratio of 31.22. Meaning, the purchaser of the share is investing €31.22 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.87%.
More news about BIOMERIEUX.
